(MRNY) YieldMax MRNA Option Income - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US88634T4691

Derivative-Income, Covered-Calls, Monthly-Options, Us-Equities, Tax-Efficient

Description: MRNY YieldMax MRNA Option Income

Tidal Trust II, trading as MRNY on NYSE ARCA, is an ETF categorized under Derivative Income, originating from the USA. As a Derivative Income ETF, its primary objective is to generate income for its investors through derivatives, which can include options, futures, and swaps. This category of ETFs is particularly appealing to investors seeking regular income in potentially low-yield environments.

The fund has $107.67 million in Assets Under Management (AUM), indicating a moderate size that can offer a balance between liquidity and the ability to maneuver in the market. The Derivative Income strategy can be sensitive to market volatility and the overall economic environment, particularly interest rates and the underlying assets performance that the derivatives are linked to.

Key Performance Indicators (KPIs) for MRNY would likely include its yield, expense ratio, and tracking error relative to its benchmark or investment objective. The yield would be crucial as it directly reflects the income generated for investors. A lower expense ratio would be favorable as it implies lower costs for investors, potentially leading to higher net returns. The tracking error is also vital as it measures how closely the ETFs performance aligns with its stated investment objective or benchmark.

Economic drivers for MRNYs performance include interest rates, market volatility, and the overall health of the underlying assets that the derivatives are based on. In a low-interest-rate environment, investors might seek higher yields through derivative income products, potentially boosting demand for MRNY. Conversely, in times of high market volatility, the value of derivatives can fluctuate significantly, impacting the ETFs performance.

Investors in MRNY should be aware of the potential risks associated with derivative instruments, including counterparty risk, liquidity risk, and the risk of significant losses due to leverage. The ETFs beta of 0.000 suggests a potentially complex or non-standard correlation with the broader market, warranting a closer examination of its investment strategy and risk profile.

MRNY ETF Overview

Market Cap in USD 95m
Category Derivative Income
TER 0.99%
IPO / Inception 2023-10-23

MRNY ETF Ratings

Growth Rating -88.9%
Fundamental -
Dividend Rating 39.1%
Return 12m vs S&P 500 -57.5%
Analyst Rating -

MRNY Dividends

Dividend Yield 12m 151.48%
Yield on Cost 5y 44.84%
Annual Growth 5y 0.00%
Payout Consistency 100.0%
Payout Ratio %

MRNY Growth Ratios

Growth Correlation 3m -43.4%
Growth Correlation 12m -81.9%
Growth Correlation 5y -88.7%
CAGR 5y -46.05%
CAGR/Max DD 3y (Calmar Ratio) -0.57
CAGR/Mean DD 3y (Pain Ratio) -0.99
Sharpe Ratio 12m -0.08
Alpha -70.02
Beta 0.000
Volatility 46.31%
Current Volume 1860.5k
Average Volume 20d 1236.8k
Stop Loss 1.5 (-8.5%)
Signal -0.36

What is the price of MRNY shares?

As of October 19, 2025, the stock is trading at USD 1.64 with a total of 1,860,500 shares traded.
Over the past week, the price has changed by -1.71%, over one month by +2.35%, over three months by -19.87% and over the past year by -50.91%.

Is YieldMax MRNA Option Income a good stock to buy?

No, based on ValueRay´s Analyses, YieldMax MRNA Option Income (NYSE ARCA:MRNY) is currently (October 2025) a stock to sell. It has a ValueRay Growth Rating of -88.91 and therefor a clear technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MRNY is around 3.34 USD . This means that MRNY is currently undervalued and has a potential upside of +103.66% (Margin of Safety).

Is MRNY a buy, sell or hold?

YieldMax MRNA Option Income has no consensus analysts rating.

What are the forecasts/targets for the MRNY price?

Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 3.8 130.5%

Last update: 2025-10-13 02:02

MRNY Fundamental Data Overview

Market Cap USD = 94.6m (94.6m USD * 1.0 USD.USD)
Beta = 0.0
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 94.6m USD (94.6m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 94.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 94.6m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 10.11% (E(94.6m)/V(94.6m) * Re(10.11%) + (debt-free company))
Discount Rate = 10.11% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)

Additional Sources for MRNY ETF

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle